Who to call at Halozyme Therapeutics, Inc., and when
Fundz watches for the moments Halozyme Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Halozyme Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Halozyme Therapeutics, Inc., from your own LinkedIn network
Halozyme Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
halozyme.comAI Executive Summary
AI-powered analysis of 8-K filing content
James Daly was elected to Halozyme Therapeutics' Board of Directors on September 28, 2026, filling a vacancy with a term extending to 2029. This board expansion brings new expertise and perspectives to the company's governance structure.
Key Takeaways
James Daly joins the Board of Directors effective September 28, 2026, with a term ending at the 2029 annual stockholder meeting
Daly will receive compensation including cash retainers, restricted stock, and stock option awards under the company's non-employee director compensation program
2 more takeaways
Filing Overview
What This Means
Halozyme Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.